Cargando…

The Potential Biomarker Panels for Identification of Major Depressive Disorder (MDD) Patients with and without Early Life Stress (ELS) by Metabonomic Analysis

OBJECTIVE: The lack of the disease biomarker to support objective laboratory tests still constitutes a bottleneck in the clinical diagnosis and evaluation of major depressive disorder (MDD) and its subtypes. We used metabonomic techniques to screen the diagnostic biomarker panels from the plasma of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Xinghua, Yang, Shuguang, Li, Wuju, Liu, Yong, Li, Zhiguo, Zhang, Yan, Li, Lingjiang, Liu, Shaojun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037179/ https://www.ncbi.nlm.nih.gov/pubmed/24870353 http://dx.doi.org/10.1371/journal.pone.0097479

Ejemplares similares

Comparison of Electroencephalography (EEG) Coherence between Major Depressive Disorder (MDD) without Comorbidity and MDD Comorbid with Internet Gaming Disorder
por: Youh, Joohyung, et al.
Publicado: (2017)

Effects of Antidepressant Treatment on Peripheral Biomarkers in Patients with Major Depressive Disorder (MDD)
por: Mosiołek, Anna, et al.
Publicado: (2021)

The neurocognitive profile of post‐traumatic stress disorder (PTSD), major depressive disorder (MDD), and PTSD with comorbid MDD
por: Koopowitz, Sheri‐Michelle, et al.
Publicado: (2021)

The possible role of the Microbiota-Gut-Brain-Axis in the etiology of Major depressive Disorder (MDD) The possible role of the Microbiota-Gut-Brain-Axis in the etiology of Major depressive Disorder (MDD) The possible role of the Microbiota-Gut-Brain-Axis in the etiology of Major depressive Disorder (MDD)
por: Pieters, T., et al.
Publicado: (2022)

The process of major depressive disorder (MDD) in women referred to the health centers
por: Rahmati-Khameneh, Souraj, et al.
Publicado: (2011)

Differential malondialdehyde (MDA) detection in plasma samples of patients with major depressive disorder (MDD): A potential biomarker
por: Alvarez-Mon, Miguel A, et al.
Publicado: (2022)

The Growing Burden of Major Depressive Disorders (MDD): Implications for Researchers and Policy Makers
por: Proudman, David, et al.
Publicado: (2021)

Identification of sex-specific urinary biomarkers for major depressive disorder by combined application of NMR- and GC–MS-based metabonomics
por: Zheng, P, et al.
Publicado: (2016)

Skin conductance responses in Major Depressive Disorder (MDD) under mental arithmetic stress
por: Kim, Ah Young, et al.
Publicado: (2019)

S-Adenosylmethionine (SAMe) in major depressive disorder (MDD): a clinician-oriented systematic review
por: Cuomo, Alessandro, et al.
Publicado: (2020)

Major Depressive Disorder (MDD) and Antidepressant Medication Are Overrepresented in High-Dose Statin Treatment
por: Leutner, Michael, et al.
Publicado: (2021)

Major depressive disorder (MDD) in adolescents with Borderline (BPD) and Shyzotypal personality disorder (STPD)
por: Kaleda, V., et al.
Publicado: (2023)

Corrigendum: Major Depressive Disorder (MDD) and Antidepressant Medication Are Overrepresented in High-Dose Statin Treatment
por: Leutner, Michael, et al.
Publicado: (2021)

Exploring the Role of Nutraceuticals in Major Depressive Disorder (MDD): Rationale, State of the Art and Future Prospects
por: Alvarez-Mon, Miguel A., et al.
Publicado: (2021)

Major depressive disorder (MDD), antidepressants, and uncontrolled hypertension: A report of intraoperative autonomic dysregulation
por: Paraskeva, Anteia, et al.
Publicado: (2022)

Clinical evaluation of Major Depressive Disorder (MDD) and Borderline Personality Disorder(BPD) in youth adolescents
por: Kaleda, V., et al.
Publicado: (2022)

Common variants in FKBP5 gene and major depressive disorder (MDD) susceptibility: a comprehensive meta-analysis
por: Rao, Shuquan, et al.
Publicado: (2016)

ENIGMA MDD: seven years of global neuroimaging studies of major depression through worldwide data sharing
por: Schmaal, Lianne, et al.
Publicado: (2020)

Combined Application of NMR- and GC-MS-Based Metabonomics Yields a Superior Urinary Biomarker Panel for Bipolar Disorder
por: Chen, Jian-jun, et al.
Publicado: (2014)

PHQ-8 Days: a measurement option for DSM-5 Major Depressive Disorder (MDD) severity
por: Dhingra, Satvinder S, et al.
Publicado: (2011)

MK4MDD: A Multi-Level Knowledge Base and Analysis Platform for Major Depressive Disorder
por: Guo, Liyuan, et al.
Publicado: (2012)

Recovery in patients with major depressive disorder (MDD): results of a 6-month, multinational, observational study
por: Novick, Diego, et al.
Publicado: (2017)

The Roles of Intracellular Chaperone Proteins, Sigma Receptors, in Parkinson’s Disease (PD) and Major Depressive Disorder (MDD)
por: Yang, Kai, et al.
Publicado: (2019)

Effects of Antidepressant Treatment on Neurotrophic Factors (BDNF and IGF-1) in Patients with Major Depressive Disorder (MDD)
por: Mosiołek, Anna, et al.
Publicado: (2021)

Altered resting-state dynamic functional brain networks in major depressive disorder: Findings from the REST-meta-MDD consortium
por: Long, Yicheng, et al.
Publicado: (2020)

Aberrant Resting-State Functional Connectivity in MDD and the Antidepressant Treatment Effect—A 6-Month Follow-Up Study
por: Li, Kangning, et al.
Publicado: (2023)

Practical Advice for Primary Care Clinicians on the Safe and Effective Use of Vortioxetine for Patients with Major Depressive Disorder (MDD)
por: Montano, C Brendan, et al.
Publicado: (2022)

A 6-Month Open-Label Study of Vortioxetine among Cancer Patients with Major Depressive Disorder (MDD)
por: Ng, Chong Guan, et al.
Publicado: (2023)

From Serotonin to Neuroplasticity: Evolvement of Theories for Major Depressive Disorder
por: Liu, Bangshan, et al.
Publicado: (2017)

Research progress of metabonomics of blood endogenous small molecules in depression
por: Zhang, Y., et al.
Publicado: (2021)

Remote assessment of disease and relapse in major depressive disorder (RADAR-MDD): a multi-centre prospective cohort study protocol
por: Matcham, F., et al.
Publicado: (2019)

Major Depressive Disorder (MDD) and Schizophrenia– Addressing Unmet Needs With Partial Agonists at the D2 Receptor: A Review
por: Mallet, Jasmina, et al.
Publicado: (2019)

Why is Diagnosing MDD Challenging?
Publicado: (2016)

Calcium-deficiency assessment and biomarker identification by an integrated urinary metabonomics analysis
por: Wang, Maoqing, et al.
Publicado: (2013)

Brain structural correlates of insomnia severity in 1053 individuals with major depressive disorder: results from the ENIGMA MDD Working Group
por: Leerssen, Jeanne, et al.
Publicado: (2020)

Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study
por: Wade, Alan G, et al.
Publicado: (2011)

Subcortical brain structure and suicidal behaviour in major depressive disorder: a meta-analysis from the ENIGMA-MDD working group
por: Rentería, M E, et al.
Publicado: (2017)

Brain-Derived Neurotrophic Factor (BDNF) as a Predictor of Treatment Response in Major Depressive Disorder (MDD): A Systematic Review
por: Zelada, Mario Ignacio, et al.
Publicado: (2023)

POSTPARTUM GAD IS A RISK FACTOR FOR POSTPARTUM MDD: THE COURSE AND LONGITUDINAL RELATIONSHIPS OF POSTPARTUM GAD AND MDD
por: Prenoveau, Jason, et al.
Publicado: (2013)

Identification of potential serum biomarkers for congenital heart disease children with pulmonary arterial hypertension by metabonomics
por: Jin, Nan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_04j93gi0si72c9tl00j50tm889